Cas:172226-79-8 tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate

CAS.NO:172226-79-8

Synonyms:tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate

Molecular Formula:C₁₉H₂₅NO₄

Molecular Weight:331.40600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:57.53000

Exact Mass:331.17800

LogP:4.26520

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate Use and application,tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate technical grade,usp/ep/jp grade.

Related News: Our quality control staff then conducts analyses in the testing laboratory to examine whether the API manufactured is ultrapure. tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate manufacturer For both Black and white women, younger age and ER-negative breast cancer were risk factors in the genes most strongly associated with breast cancer, including BRCA1, BRCA2 and PALB2. tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate supplier There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space. tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate vendor This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. tert-butyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)indole-1-carboxylate factory For both Black and white women, younger age and ER-negative breast cancer were risk factors in the genes most strongly associated with breast cancer, including BRCA1, BRCA2 and PALB2.